Who we are
Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Neovii was founded following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals.
What Neovii stands for
Location
Neovii’s global headquarters are located in Rapperswil, Switzerland, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approximately 150 employees and has a presence in more than 40 countries worldwide.
Grafalon history
1979
ATG-Fresenius® S (now Grafalon®) is manufactured for the first time1981
First clinical use in organ transplantation1989
First clinical use of the ATG-Fresenius® S polyclonal antibody in stem cell transplantation2010
FDA grants orphan drug status and fast track designation for the development of ATG-Fresenius® S for prevention of GVHD in the United States2011
German Health Authorities (PEI) approves ATG-Fresenius® for prevention of graft-versus-host disease (GVHD) in adults after allogeneic stem cell transplantation (SCT) in Germany.2013
Fresenius Biotech becomes Neovii2014
Neovii global headquarters are established in Rapperswil, Switzerland2015
ATG-Fresenius® S is re-branded and launched as GRAFALON®.Core Values
Passion
We are inspired by the meaningful work we do and are passionately committed to success.
Openness
We are open-minded, implement creative solutions and encourage entrepreneurship.
Ambition
We set clear, ambitious targets.
Our vision
Neovii aspires to be a fully integrated global pharmaceutical company with several franchises focused on diseases with unmet needs. We continually support customers up and down the value chain and are always in pursuit of maximizing total patient care.
We believe that our competencies and strengths combined with our values and culture make Neovii an employer of choice.